July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
QuantiFERON-TB Gold Test Results and Clinical Manifestations In New Uveitis Patients at a Tertiary Non-endemic Center
Author Affiliations & Notes
  • Shuk Kei Cheng
    Uveitis, National Institute of Health/NEI, DC, Washington, United States
  • Sonny Caplash
    Uveitis, National Institute of Health/NEI, DC, Washington, United States
  • Ian Thompson
    Uveitis, National Institute of Health/NEI, DC, Washington, United States
  • Sapna Gangaputra
    Uveitis, National Institute of Health/NEI, DC, Washington, United States
  • H Nida Nida Sen
    Uveitis, National Institute of Health/NEI, DC, Washington, United States
  • Footnotes
    Commercial Relationships   Shuk Kei Cheng, None; Sonny Caplash, None; Ian Thompson, None; Sapna Gangaputra, None; H Nida Sen, None
  • Footnotes
    Support  National Eye Institute Intramural Research Program
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4187. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shuk Kei Cheng, Sonny Caplash, Ian Thompson, Sapna Gangaputra, H Nida Nida Sen; QuantiFERON-TB Gold Test Results and Clinical Manifestations In New Uveitis Patients at a Tertiary Non-endemic Center. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4187.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To report on frequency of positive QuantiFERON-TB Gold (QFT-G) assays among uveitis patients and determine whether differences exist in clinical characteristics between QFT-G positive and negative patients.

Methods : Retrospective chart review was performed to examine 263 new patients with uveitis who received QFT-G assays as a standard laboratory work-up under a clinical research protocol at a tertiary hospital in a non-endemic location. We analyzed patient demographics such as gender, race, age at presentation to tertiary center, QFT-G test results, and anatomic locations of uveitis.

Results : QFT-G test was positive in 36/263 patients (13.69%). Mean age at presentation was 48.8 years for QFT-G positive patients (median: 49.5, range: 21-76); for QFT-G negative patients, 44 years (median 44, range 9-91) (p=0.14). Both QFT-G-positive and QFT-G-negative groups had the same male-to-female ratio, 1:1.2. Non-Hispanic Whites were less likely to test positive on QFT-G (OR,0.2; 95% CI, 0.09-0.49; p=0.004) whereas Asians were more likely to test positive (OR, 3.1; 95%CI, 1.39-7.04, p=0.0059). In terms of anatomic location of uveitis, patients tested positive with QFT-G were more likely to have anterior uveitis (OR, 2.5; 95%CI, 1.17-5.31; p=0.02) compared to those who tested negative. There was no difference for posterior uveitis (OR, 0.81; 95%CI, 0.37-1.78), intermediate (OR,0.40; 95%CI, 0.13-1.16; p=0.60), panuveitis (OR,0.58; 95%CI, 0.25-1.33; p=0.20), or retinal vasculitis (OR,1.5; 95%CI, 0.17-12.74; p=0.72).

Conclusions : In this cohort from a non-endemic tertiary center, we found that 13.69% of new uveitis patients tested QFG-T-positive. There were no differences in age at presentation, sex, the prevalence of posterior segment uveitis, and retinal vasculitis. Patients who tested QFT-G positive were more likely to have anterior uveitis. Asians were more likely to test positive for QTF-G.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×